The mucosal immune system of the upper respiratory tract and recent progress in mucosal vaccines.
Administration, Intranasal
Animals
Antigens, Bacterial
Haemophilus influenzae
/ immunology
Humans
Immune System
Immunity, Mucosal
Immunoglobulin A, Secretory
Mice
Mucous Membrane
Phosphorylcholine
/ immunology
Pneumococcal Vaccines
Respiratory System
/ immunology
Rhinitis, Allergic
/ prevention & control
Streptococcus pneumoniae
/ immunology
Vaccines
/ immunology
Mucosal adjuvant
Mucosal immune system
Mucosal vaccine
Phosphorylcholine
Secretory IgA
Upper respiratory tract
Journal
Auris, nasus, larynx
ISSN: 1879-1476
Titre abrégé: Auris Nasus Larynx
Pays: Netherlands
ID NLM: 7708170
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
05
06
2021
accepted:
06
07
2021
pubmed:
27
7
2021
medline:
8
3
2022
entrez:
26
7
2021
Statut:
ppublish
Résumé
The mucosal immune system prevents microorganism invasion through mucosal surfaces and consists of inductive and effector sites. Nasopharynx-associated lymphoid tissue (NALT) functions as an inductive site, inducing mucosal immune responses in the upper respiratory tract. It follows that intranasal vaccines may prevent upper respiratory infections. To induce and enhance the immune response by administering inactivated antigens intranasally, mucosal adjuvants have been developed, including mutant cholera toxin and cationic cholesteryl pullulan nanogel, which do not accumulate in the central nervous system. Moreover, multivalent pneumococcal polysaccharide conjugate vaccines are used to prevent invasive pneumococcal infections and otitis media, although they only provide moderate protection against acute otitis media because non-vaccine serotypes of Streptococcus pneumoniae and Haemophilus influenzae also cause this infection. To address this problem, pneumococcal surface protein A of S. pneumoniae and P6 of H. influenzae are used as broad-spectrum vaccine antigens. Alternatively, phosphorylcholine (PC) is present in the cell walls of both gram-positive and gram-negative bacteria and induces immune responses through antigenic activity. The significant effects of PC as a mucosal vaccine have been demonstrated through intranasal and sublingual immunization in mice. Furthermore, intranasal administration of PC reverses increases in IgE levels and prevents allergic rhinitis. After immunization with pneumococcal polysaccharide conjugate vaccine, intranasal immunization with PC boosts immune responses to vaccine strains and to PC itself. Thus, PC may be useful as a mucosal vaccine to prevent upper respiratory infections and allergic rhinitis, and it could be used as a booster to the currently used pneumococcal vaccine as it protects against non-vaccine strains.
Identifiants
pubmed: 34304944
pii: S0385-8146(21)00195-4
doi: 10.1016/j.anl.2021.07.003
pii:
doi:
Substances chimiques
Antigens, Bacterial
0
Immunoglobulin A, Secretory
0
Pneumococcal Vaccines
0
Vaccines
0
Phosphorylcholine
107-73-3
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-10Informations de copyright
Copyright © 2021. Published by Elsevier B.V.